Ehsan Vaghefi, CEO and co-founder of Toku, found inspiration in his father's blindness to pioneer innovative health technology. Toku's flagship product, CLAiR, is an AI-powered retina scan platform detecting cardiovascular risks, stroke, and type 2 diabetes in a remarkable 20 seconds.
The FDA's recent grant of "breakthrough device status" expedites CLAiR's journey to market, positioning Toku to be the first to offer an affordable, non-invasive method for cardiovascular disease detection in the U.S.
Toku, headquartered in San Diego after originating in Auckland, plans pivotal trials for CLAiR in mid-2024 with a market rollout targeted by the end of 2025. The startup secured an $8 million Series A funding round from key investors, including National Vision and Topcon Healthcare.
While other startups, like Google and Alphabet's Verily, explore similar avenues, Toku distinguishes itself through strategic partnerships and a commitment to privacy compliance, ensuring adherence to HIPAA and ISO 13483 regulations in handling patient data.
As the healthcare landscape continues to evolve, Toku positions CLAiR as a transformative tool to be deployed in retail optometry, primary care offices, ophthalmology clinics, and pharmacies equipped with retinal cameras.
This breakthrough technology identifies elevated cardiovascular risk during routine eye exams, streamlining timely referrals to primary care providers for additional tests and establishing Toku as a pioneering force in accessible, affordable, and seamlessly integrated cardiovascular risk detection.
Click here to read the original news story.